iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

India's Pharma exports up by 29% in 2008-09

16 Apr 2014 , 05:54 AM

Anand Sharma, Union Minister of Commerce and Industry, while addressing the Indo-Africa Pharma Business Meet in Hyderabad today, has stated that the exports of drugs, pharmaceuticals and fine chemicals for the year 2008-09 stood at Rs395.38bn (around US$9.35bn), registering a growth of about 29% over the last year.

“In recent times the Indian pharmaceutical sector has emerged as one of the major contributors to Indian exports with export earnings rising from a negligible amount in early 1990s to Rs291.39bn (US$7.24bn) by 2007-08. The exports of Drugs, pharmaceuticals & fine chemicals of India have grown at a compounded annual growth rate of 17.8% during the five-year period 2003-04 to 2007-08”, the Minister added.

Sharma also distributed the awards to the leading exporters of the pharma sector. Chief Minister of Andhra Pradesh, K. Rosaiah, was also present as the Guest of Honour at this function. The Minister also announced the Government of India’s decision to establish National institute of Design in Hyderabad as a mark of respect to the departed Chief Minister Y.S. Rajshekhar Reddy.

Speaking on the occasion, Sharma stated that in generic medicines sector i.e., tablets and capsules, injectables and infusion, oral solutions, ointments and creams, Indian companies have established their lead in most of the markets including Africa.

He further added that the growing export of India in African countries has started causing concern in multinational companies who have started a campaign as Indian generic medicines being counterfeit and substandard. Recognizing the contribution of Indian pharmaceutical industry in exports of the country, Anand Sharma informed that several benefits have been extended to the industry in the Foreign Trade Policy announced recently — viz., (i) Additional resources have been made available under the Market Development Assistance Scheme and Market Access Initiative Scheme.

PHARMEXCIL, the Export Promotion Council has been provided funds for Brand Promotion of Indian pharmaceutical industry in Africa under MAI Scheme. (ii) Incentive available under Focus Market Scheme has been raised from 2.5% to 3%. Pharma sector will also benefit with this. (iii) Incentive under Focus Product Scheme has been raised from 1.25% to 2%. (iv) Pharmaceutical has been included in Market linked Focus Product Scheme. Thus exports to Algeria, Egypt, Kenya, Nigeria, South Africa and Tanzania will be eligible for benefit under this Scheme.

(v) Zero duty has been introduced under EPCG Scheme for aiding technological upgradation for pharma sector also. The 3-day (25-27 September) Meet is being attended by Drug Regulatory Authorities from African countries, viz., South Africa, Kenya, Nigeria, Ghana, Zambia and Uganda along with the Health Minister of Kenya and DG-NAFDAC, Nigeria. During the event, apart from Buyer-Seller Meet, Drug Controller General of India will make a presentation on Drug Regulation Mechanism in India before the Drug Regulators of African countries

sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Most Read News

Bansal Wire Industries IPO opens today
3 Jul 2024|12:25 PM
Emcure Pharmaceuticals IPO opens today
3 Jul 2024|12:20 PM
V-Mart Retail rises to a 52-week high
3 Jul 2024|11:50 AM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.